VI-1121 for the Treatment Alzheimer's Disease | NCT01428362 | Trialant

VI-1121 for the Treatment Alzheimer's Disease | NCT01428362 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Placebo/VI-1121	Experimental	Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period.	Drug: VI-1121 Drug: Placebo
VI-1121/Placebo	Experimental	Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period.	Drug: VI-1121 Drug: Placebo

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
The primary efficacy variable is the change in Alzheimer's Disease Assessment-Cognitive Subscale (ADAS-Cog) score from baseline to Week 12 of each treatment period.		12 weeks

Secondary Outcomes

Measure	Description	Time Frame
The secondary efficacy endpoint is the mean change in Mini-Mental State Examination (MMSE) score from baseline to Week 12 of each treatment period.		12 weeks
Percentage of subjects who achieve 3-point improvement in ADAS-Cog score from baseline to Week 12 of each treatment period.

Condition Browse Module